The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone.

Key Facts About Innovative Medicines

Key Facts about innovative medicines: Fact 1:  America's biopharmaceutical industry invests 90 billion dollars in research and development. Fact 2: In 2017, the US Food and Drug Administration approved 59 new medicines. Of those, 42 were first approved in the United States before receiving approval in any other country. Fact 3: More than 7000 medicines and treatments are in development globally right now. Fact 4: Roughly 3500 compounds are currently being studied in the United States alone-more than in any other region.

PhRMA History

PhRMA was formed in 1958 to represent America’s biopharmaceutical research companies and help promote smart public policy that supports medical research to address patient needs. Headquartered in Washington, D.C., with offices in leading biopharmaceutical research communities, PhRMA advocates in the United States and around the world for policies that support the discovery and development of innovative medicines. Our policy priorities include: explaining the increased complexity and risk of the research and development process; reinforcing the need for investment in R&D; ensuring broad access to and appropriate use of medicines, and emphasizing the importance of strong intellectual property incentives for new medicines.


Our 13 offices are located across the United States and in Beijing, People's Republic of China, Dubai, United Arab Emirates, and Tokyo, Japan.

Washington, D.C. [Headquarters] Albany, NY Atlanta, GA Baton Rouge, LA
 Denver, CO Foxboro, MA Indianapolis, IN Olympia, WA
 Sacramento, CA St. Paul, MN Beijing, People’s Republic of China Dubai, United Arab Emirates
 Tokyo, Japan